Tuesday, November 24,  2:17 am

Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.

Roche Holding AG assured Genentech Inc. shareholders that holdouts in its tender offer have no downside and a potential to receive greater value for their shares after data about cancer drug Avastin comes available next month.

Roche updated the language in its tender offer late Monday to amend and clarify its intentions should it own 90% or more of Genentech shares at the completion of its offer. With its initial filing of the tender offer for the 44.2% of Genentech it does not own at $86.50 per share, Roche stated that if it gets 90% it intends to consummate a merger with Genentech for the same price subject to the Affiliation Agreement between the companies.

This is a free preview of the content available in The Deal Pipeline. Subscribers enjoy access to the full story, as well as second-to-none research tools.

To request a demo, or, if you are an existing user to The Deal Pipeline, log in to your account, please scroll down and click the button.

Dig deeper, with Pipeline.

• 755 in-depth reports of M&A deals in the Healthcare sector
• 612 company pages related to pharmaceuticals
• 367 articles related to Genentech Inc.
• 297 articles related to Roche Holding AG
• 10 years of news and analysis archives from the voice of The Deal Economy
  

Most searched keywords

• Deutsche Bank
• Skadden Arps
• Pinnacle Foods
• Concho Resources
• Agrium Inc.
• Birds Eye
• Cantor Fitzgerald
  
• Credit Suisse
• Windstream Corp.
  
• Goldman Sachs